Channel
AI models, clinical data infrastructure, imaging, diagnostics and workflow automation across healthcare settings.
AI is reshaping the healthcare industry, from diagnostic assistance to patient management, with technology implementation accelerating. This article analyzes key trends, market impacts, and future challenges.
A comprehensive analysis of AI in healthcare adoption statistics for 2025-2026, covering market size, ROI, FDA clearances, and the widening gap between administrative and clinical diagnostic use.
Discuss the impact of AI on employment in the healthcare industry, analyzing which positions are at risk, which are safe, and the new opportunities created by AI.
A recent survey by the ZS Impact Institute shows that 58% of American patients research their symptoms using AI or search engines before seeing a doctor, and 18% have directly used AI tools. The healthcare system is facing pressure from the transformation of patient behavior.
Artificial intelligence is accelerating drug development for central nervous system diseases. Insilico Medicine and SK Biopharmaceuticals announced a collaboration to discover neuroimmune drug candidates using Insilico's Pharma.AI platform, with potential milestone payments of up to $2.5 billion.
Medical AI is moving from single prediction to a new stage of integrating predictive and generative AI. By embedding into clinical workflows and adopting hybrid infrastructure, it helps medical institutions transform data insights into actionable clinical actions, improving patient outcomes and reducing the burden on doctors.
Artificial intelligence is revolutionizing decision-making in the biopharmaceutical industry. From drug discovery to clinical trials, AI not only accelerates processes but also forces companies to rethink how to integrate data, expert judgment, and governance structures. This article provides an in-depth analysis of the industry impact and future direction of this trend.
GE HealthCare will showcase AI software, imaging systems, radiopharmaceuticals, and localized production solutions related to nuclear medicine during SNMMI 2026, reflecting that nuclear medicine is moving from competition among single devices toward a phase of expansion driven by “platformization + ecosystemization.”